Metraipolis › archive › dc_286affa3c359
AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab — Europe PMC PMID:42358545
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42358545
- DOI
- 10.3389/fonc.2026.1867932
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T14:37:50.217Z
- SHA-256 of the archived text
b800cf7644054c118c11648d8483ec99e7805ad4b9ead32659eb79c69d840d8d- Stable URL of this page
https://metraipolis.com/documento/dc_286affa3c359
How to cite
AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab — Europe PMC PMID:42358545 — Europe PMC (en), https://europepmc.org/article/MED/42358545 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_286affa3c359 (Metraipolis archive dc_286affa3c359, sha256 b800cf7644054c118c11648d8483ec99e7805ad4b9ead32659eb79c69d840d8d)
BibTeX
@misc{dc286affa3c359,
title = {AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab — Europe PMC PMID:42358545},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42358545},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_286affa3c359; sha256 b800cf7644054c118c11648d8483ec99e7805ad4b9ead32659eb79c69d840d8d},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42358545. Agents can read the archived copy with the MCP tool read_document.